Real-world costs per life-year of targeted therapy, incidence, lifetime health impact, and medical costs of renal cell carcinoma in Taiwan
Frontiers in Public Health · 15.04.2026 · 14
DOI: 10.3389/fpubh.2026.1808050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 15.04.2026. Verfasst von Chin-Heng Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, Tungs' Taichung Metroharbor Hospital, Taichung City, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Health Care Costs, Molecular Targeted Therapy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The incidence of renal cell carcinoma (RCC) and its associated economic burden have risen significantly in Taiwan. While targeted therapy has become a standard treatment, its real-world effectiveness and cost-effectiveness remain to be fully evaluated.
Methods
This population-based cohort study utilized the Taiwan National Health Insurance Research Database and Cancer Registry to analyze 14,131 RCC cases diagnosed between 1998 and 2016. Key outcomes included life expectancy (LE), loss of LE, and lifetime medical costs.
Results
The cumulative incidence rate of RCC increased from 0.37 to 0.73% in men and from 0.23 to 0.36% in women. Significant LE loss was observed, particularly in patients under 50 years of age (14.38 years in men; 12.89 years in women). In advanced cases, targeted therapy yielded a slightly higher LE (4.43 years) compared to non-targeted therapy (3.63 years); however, the loss of LE was similar between groups.
Conclusion
The real-world relationship between survival outcomes and lifetime medical costs of targeted therapy in Taiwan suggests suboptimal efficiency under current clinical practice. These findings suggest a need to re-evaluate reimbursement strategies by considering pharmacogenomic heterogeneity, implementing genomic profiling for precision medicine, and transitioning toward more effective combination therapy paradigms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Urology, Department of Surgery, Tungs' Taichung Metroharbor Hospital, Taichung City, Taiwan.
- Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung City, Taiwan.
- Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung City, Taiwan.
- Department of Nursing, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan.
- Department of Allergy, Immunology, and Rheumatology, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung City, Taiwan.
Zitieren
APA
Lu, C. H., Tung, M. C., Ou, Y. C., Chiu, Y. M., Tse, S. S., & Chang, C. C. (2026). Real-world costs per life-year of targeted therapy, incidence, lifetime health impact, and medical costs of renal cell carcinoma in Taiwan. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1808050
Vancouver
Lu CH, Tung MC, Ou YC, Chiu YM, Tse SS, Chang CC. Real-world costs per life-year of targeted therapy, incidence, lifetime health impact, and medical costs of renal cell carcinoma in Taiwan. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1808050
BibTeX
@article{Lu2026,
author = {Lu, Chin-Heng and Tung, Min-Che and Ou, Yen-Chuan and Chiu, Ying-Ming and Tse, Siu-San and Chang, Chia-Che},
title = {Real-world costs per life-year of targeted therapy, incidence, lifetime health impact, and medical costs of renal cell carcinoma in Taiwan},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.1808050}
}
EUVIMED